Claris Lifesciences has received USFDA approval for generic anaesthetic Bupivacaine injection. The new drug Bupivacaine hydrochloride will be sold in 8.25 per cent dextrose injection USP 7.5 mg/mL, single dose ampules with 2 ml fill volumes. The injection is indicated for the production of local or regional anaesthesia or analgesia for surgery, diagnostic and therapeutic procedures.
Company Profile : Claris Lifesciences Ltd
Leave a Reply